The effects of the protease inhibitor, aprotinin, on the course of shock induced by endotoxin in cats

B. Hughes, J. Parratt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

1. The administration of endotoxin derived from Escherichia coli to anaesthetized cats resulted, within the first 5 min, in an initial increase in right atrial pressure and a reduction in systemic arterial blood pressure. Over the next 2 h shock was characterized by a reduced cardiac output, tachycardia, reduced arterial pH and an increased level of lactate. The survival rate at the end of the 8 h experimental period was only 10%. 2. The protease inhibitor aprotinin (Trasylol), given as a continuous intravenous infusion 1000 kallikrein inhibitor units (k.i.u.) kg-1 h-1 together with a bolus of 40,000 k.i.u. kg-1, significantly inhibited the severity and incidence of the initial endotoxin response (increase in right atrial pressure and systemic hypotension), perhaps suggesting the direct or indirect involvement of kinins. 3. Aprotinin did not reduce the delayed effects of endotoxin (sustained reduction in cardiac output, lacticacidosis), nor did it improve survival at 8 h. Indeed, there was some evidence that aprotinin exaggerated the delayed effects of endotoxin in this model.

Original languageEnglish
Pages (from-to)399-403
Number of pages5
JournalBritish Journal of Pharmacology
Volume86
Issue number2
Publication statusPublished - 1985

Fingerprint

Aprotinin
Protease Inhibitors
Endotoxins
Shock
Cats
Kallikreins
Atrial Pressure
Cardiac Output
Kinins
Intravenous Infusions
Tachycardia
Hypotension
Lactic Acid
Arterial Pressure
Incidence

ASJC Scopus subject areas

  • Pharmacology

Cite this

The effects of the protease inhibitor, aprotinin, on the course of shock induced by endotoxin in cats. / Hughes, B.; Parratt, J.

In: British Journal of Pharmacology, Vol. 86, No. 2, 1985, p. 399-403.

Research output: Contribution to journalArticle

@article{90590356ae9e49d189f989f04062099a,
title = "The effects of the protease inhibitor, aprotinin, on the course of shock induced by endotoxin in cats",
abstract = "1. The administration of endotoxin derived from Escherichia coli to anaesthetized cats resulted, within the first 5 min, in an initial increase in right atrial pressure and a reduction in systemic arterial blood pressure. Over the next 2 h shock was characterized by a reduced cardiac output, tachycardia, reduced arterial pH and an increased level of lactate. The survival rate at the end of the 8 h experimental period was only 10{\%}. 2. The protease inhibitor aprotinin (Trasylol), given as a continuous intravenous infusion 1000 kallikrein inhibitor units (k.i.u.) kg-1 h-1 together with a bolus of 40,000 k.i.u. kg-1, significantly inhibited the severity and incidence of the initial endotoxin response (increase in right atrial pressure and systemic hypotension), perhaps suggesting the direct or indirect involvement of kinins. 3. Aprotinin did not reduce the delayed effects of endotoxin (sustained reduction in cardiac output, lacticacidosis), nor did it improve survival at 8 h. Indeed, there was some evidence that aprotinin exaggerated the delayed effects of endotoxin in this model.",
author = "B. Hughes and J. Parratt",
year = "1985",
language = "English",
volume = "86",
pages = "399--403",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The effects of the protease inhibitor, aprotinin, on the course of shock induced by endotoxin in cats

AU - Hughes, B.

AU - Parratt, J.

PY - 1985

Y1 - 1985

N2 - 1. The administration of endotoxin derived from Escherichia coli to anaesthetized cats resulted, within the first 5 min, in an initial increase in right atrial pressure and a reduction in systemic arterial blood pressure. Over the next 2 h shock was characterized by a reduced cardiac output, tachycardia, reduced arterial pH and an increased level of lactate. The survival rate at the end of the 8 h experimental period was only 10%. 2. The protease inhibitor aprotinin (Trasylol), given as a continuous intravenous infusion 1000 kallikrein inhibitor units (k.i.u.) kg-1 h-1 together with a bolus of 40,000 k.i.u. kg-1, significantly inhibited the severity and incidence of the initial endotoxin response (increase in right atrial pressure and systemic hypotension), perhaps suggesting the direct or indirect involvement of kinins. 3. Aprotinin did not reduce the delayed effects of endotoxin (sustained reduction in cardiac output, lacticacidosis), nor did it improve survival at 8 h. Indeed, there was some evidence that aprotinin exaggerated the delayed effects of endotoxin in this model.

AB - 1. The administration of endotoxin derived from Escherichia coli to anaesthetized cats resulted, within the first 5 min, in an initial increase in right atrial pressure and a reduction in systemic arterial blood pressure. Over the next 2 h shock was characterized by a reduced cardiac output, tachycardia, reduced arterial pH and an increased level of lactate. The survival rate at the end of the 8 h experimental period was only 10%. 2. The protease inhibitor aprotinin (Trasylol), given as a continuous intravenous infusion 1000 kallikrein inhibitor units (k.i.u.) kg-1 h-1 together with a bolus of 40,000 k.i.u. kg-1, significantly inhibited the severity and incidence of the initial endotoxin response (increase in right atrial pressure and systemic hypotension), perhaps suggesting the direct or indirect involvement of kinins. 3. Aprotinin did not reduce the delayed effects of endotoxin (sustained reduction in cardiac output, lacticacidosis), nor did it improve survival at 8 h. Indeed, there was some evidence that aprotinin exaggerated the delayed effects of endotoxin in this model.

UR - http://www.scopus.com/inward/record.url?scp=0021984572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021984572&partnerID=8YFLogxK

M3 - Article

C2 - 2413945

AN - SCOPUS:0021984572

VL - 86

SP - 399

EP - 403

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -